Haleon plc Files 6-K on Share Transactions
Ticker: HLNCF · Form: 6-K · Filed: Sep 18, 2024 · CIK: 1900304
Sentiment: neutral
Topics: share-transaction, 6-K, disclosure
TL;DR
Haleon bought back its own stock on Sept 18, 2024. Watch EPS.
AI Summary
On September 18, 2024, Haleon plc filed a Form 6-K reporting a transaction in its own shares. The filing details the company's activities related to its share repurchases or other dealings in its own equity.
Why It Matters
This filing provides insight into Haleon's capital allocation strategy and its direct impact on the number of outstanding shares, which can influence earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share transactions, not indicative of new risks.
Key Players & Entities
- Haleon plc (company) — Registrant
- 001-41411 (company) — Commission File Number
- September 18, 2024 (date) — Filing Date and Transaction Date
FAQ
What specific type of transaction in its own shares did Haleon plc report?
The filing, Exhibit 99.1, is titled 'Transaction in Own Shares' and was filed on September 18, 2024, indicating the company engaged in dealings with its own equity.
What is Haleon plc's commission file number with the SEC?
Haleon plc's commission file number is 001-41411.
When was this Form 6-K filed?
This Form 6-K was filed on September 18, 2024.
Does Haleon plc file annual reports under Form 20-F or 40-F?
Haleon plc files annual reports under cover of Form 20-F, as indicated by the checkmark in the filing.
What is Haleon plc's principal executive office address?
Haleon plc's principal executive office is located at Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY.
Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-09-18 13:36:39
Filing Documents
- haleonplc.htm (6-K) — 31KB
- 0001654954-24-012059.txt ( ) — 32KB
From the Filing
IN OWN SHARES haleonplc   UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2024   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1  18 September 2024 - “Transaction in Own Shares”         99.1           Haleon plc:   Transaction in own shares   18 September 2024:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of the following number of ordinary shares of £0.01 each in the Company (the "Shares") for cancellation   under its share buyback programme announced on 1 August 2024   (the "Buyback Programme").   Date of purchase: 18 September 2024 Number of Shares purchased: 650,166 Highest price paid per Share (p): 400.5000 Lowest price paid per Share (p): 395.1000 Volume weighted average price paid per Share (p): 398.3941   Following the settlement of the above, the Company's registered share capital consists of 9,117,176,266 ordinary shares. This figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5s(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/7665E_1-2024-9-18.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Sonya Ghobrial   +44 7392 784784 Zoë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Gemma Thomas +44 7985 175048 Emma White +44 7823 523562     Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .                SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 18, 2024 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary